- Home
- INSM vs FWONK Comparison
INSM vs FWONK Comparison
Compare INSM & FWONK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INSM | FWONK |
|---|---|---|
| Founded | 1988 | 1950 |
| Country | United States | United States |
| Employees | N/A | 1674 |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0B | 25.1B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | INSM | FWONK |
|---|---|---|
| Price | $108.13 | $102.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 24 | 8 |
| Target Price | ★ $201.17 | $110.88 |
| AVG Volume (30 Days) | ★ 3.6M | 2.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $182.31 | $24.56 |
| Revenue Next Year | $65.19 | $5.52 |
| P/E Ratio | ★ N/A | $107.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $90.39 | $80.15 |
| 52 Week High | $212.75 | $109.36 |
Technical Indicators
Market Signals| Indicator | INSM | FWONK |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 68.89 |
| Support Level | $98.90 | $93.43 |
| Resistance Level | $119.54 | $105.41 |
| Average True Range (ATR) | 4.50 | 3.02 |
| MACD | 0.10 | 0.41 |
| Stochastic Oscillator | 32.44 | 88.58 |
Price Performance
Historical ComparisonAbout INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
About FWONK Liberty Media Corporation Series C Liberty Formula One
Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. It operates in two reportable segment Formula 1 and MotoGP. It generates majority of its revenue from the Formula 1 segment. The company derives its maximum revenue from United Kingdom.